Identifying therapeutic biomarkers of zoledronic acid by metabolomics

• Hoofdauteurs: Xiang Li (Auteur), Zi-Yuan Wang (Auteur), Na Ren (Auteur), Zhan-Ying Wei (Auteur), Wei-Wei Hu (Auteur), Jie-Mei Gu (Auteur), Zhen-Lin Zhang (Auteur), Xiang-Tian Yu (Auteur), Chun Wang (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Zoledronic acid (ZOL) is a potent antiresorptive agent that increases bone mineral density (BMD) and reduces fracture risk in postmenopausal osteoporosis (PMOP). The anti-osteoporotic effect of ZOL is determined by annual BMD measurement. In most cases, bone turnover markers function as early indica...